ARCHIVES

FDA unlikely to pull Iressa from market. Iressa a case study in how not to develop a drug, ODAC member says.

This article is from The Cancer Letter archive.

Vol. 31 No. 13 | April 1, 2005

Download PDF Visit The Full Archive

Related Articles

1.7% Cut Expected in NCI Budget Under Deficit Agreement

November 24, 1989

HEW Ruling Limits Distribution Of Chemicals From Repository To Contractors, Government

May 7, 1976

Research teams link response to Iressa to mutations in EGF receptor.

April 30, 2004

Researchers Find Genetic Alterations in Triple-Negative Cancers Following Treatment

January 25, 2013

Norris Cotton Cancer Center wins core grant renewal.

October 10, 2003

NCI To Cut Smoking Intervention Study By 20%, Says Chemoprevention Accrual Has Priority

November 6, 1992